Beta Bionics To Integrate iLet Bionic Pancreas With Abbott's Upcoming Dual Glucose-Ketone Sensor, Advancing Automated Insulin Delivery In The U.S.

Author: Benzinga Newsdesk | June 19, 2025 07:05am

Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, announced its intention to integrate its iLet Bionic Pancreas automated insulin delivery (AID) system with Abbott's future dual glucose-ketone sensor in the U.S.

The iLet represents a significant advancement in diabetes care as the first and only AID system that makes 100% of insulin dosing decisions automatically. With the iLet, people living with diabetes can achieve excellent clinical outcomes without the burden of carb counting* or manual insulin correction calculations. The system currently supports Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring sensor, and this future design further extends the collaboration between Beta Bionics and Abbott, reinforcing their shared commitment to bringing cutting-edge diabetes solutions to the market.

Posted In: ABT BBNX